-
GKT137831 in Redox and Ferroptosis Workflows
2026-08-27
GKT137831 helps separate Nox1/Nox4-driven reactive oxygen species signaling from downstream lipid-peroxidation and membrane-failure phenotypes. This practical guide combines vascular, fibrotic, and ferroptosis assay workflows with controls that improve interpretation and reproducibility.
-
Triacetin Workflows for Translational Research
2026-08-27
Triacetin, or glyceryl triacetate, supports distinct workflows spanning glioblastoma apoptosis studies, metabolic signaling, and ocular formulation screening. This practical guide shows how to control concentration, exposure, formulation, and orthogonal readouts while avoiding the major confounder: Triacetin can function as both a carrier and a bioactive lipid-related reagent.
-
Vacuolin-1 and the Translational Lysosome
2026-08-26
Lysosomal exocytosis is emerging as an active driver of tissue pathology rather than a passive consequence of storage. This thought-leadership guide connects Vacuolin-1-enabled perturbation with disease modeling, assay strategy, plasma membrane repair research, and translational decision-making.
-
Separating Growth Arrest from Cell Death in Cancer Assays
2026-08-26
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measurements capture different components of an in vitro cancer drug response. Its central practical implication is that growth inhibition, cell killing, and their timing should be measured and interpreted separately when comparing drug mechanisms or assay results.
-
Ionomycin Free Acid in FAK–Calcium Signaling
2026-08-25
A translational framework for using Ionomycin free acid as a controlled calcium perturbation to investigate the FAISL–FAK–Calpain 2 axis in triple-negative breast cancer, while defining the boundaries between established evidence and testable hypotheses.
-
miR-196a, MYC, and EAC Aggressiveness
2026-08-25
García-Castillo et al. identify miR-196a as a functional driver of esophageal adenocarcinoma aggressiveness, linking NFKBIA loss and VCP downregulation to c-MYC accumulation, TERT activation, NFκB signaling, epithelial-to-mesenchymal transition, and increased motility. The study combines cell-based perturbation experiments with Barrett’s esophagus tissue analysis, providing a mechanistic framework for interpreting progression from premalignant disease to invasive EAC.
-
Cy5 Hydrazide for Carbonyl Assay Design
2026-08-24
Cy5 hydrazide enables sensitive carbonyl-reactive fluorescent labeling of oxidized proteins, glycoproteins, oligonucleotides, and nanoparticle interfaces. This guide focuses on assay architecture, formulation-aware controls, and interpretation beyond simple fluorescence intensity.
-
Recombinant Human FGF-19 Assay Design Guide
2026-08-24
Recombinant Human FGF-19 enables controlled investigation of FGFR4 signaling, metabolic regulation, and assay performance. This guide connects FGF-19 assay architecture with mechanistic lessons from sepsis-associated kidney injury without overstating evidence across biological domains.
-
Triacetin and Aldehyde Formation in E-Cigarette Aerosols
2026-08-23
The ACS Omega study used carbon-13 labeling and proton and carbon-13 NMR to determine how triacetin changes aldehyde chemistry during electronic-cigarette aerosolization. Its central finding is that triacetin hydrolysis releases acetic acid, which catalyzes degradation of propylene glycol and glycerol rather than simply serving as a direct aldehyde precursor.
-
5-(N,N-dimethyl)-Amiloride in Endothelial Studies
2026-08-22
Use 5-(N,N-dimethyl)-Amiloride hydrochloride to connect Na+/H+ exchanger activity with intracellular pH regulation, endothelial barrier failure, and ion-transport phenotypes. This workflow pairs DMA perturbation with moesin, permeability, and inflammatory readouts to distinguish mechanism from nonspecific toxicity.
-
ML365, NLRP3, and Postoperative Cognitive Impairment
2026-08-22
A 2024 Brain Research study examined whether ML365 could reduce postoperative cognitive impairment in aged mice after exploratory laparotomy. The findings connect K2P channel pharmacology with hippocampal NLRP3 inflammasome signaling, while also highlighting the need for direct target-engagement and translational studies.
-
Starvation, ER Ca2+, and Cell Fate in Bombyx mori
2026-08-21
A 2026 study in Bombyx mori identifies an ER-Ca2+-calpain pathway that converts starvation-induced autophagy into apoptosis in the insect fat body. Its use of 2-APB to suppress IP3R-linked calcium signaling provides pharmacological evidence that calcium-store dysfunction helps determine cell fate during sustained nutrient deprivation.
-
Relative Versus Fractional Viability in Cancer Models
2026-08-20
Hannah R. Schwartz’s dissertation distinguishes relative viability, which combines growth inhibition and cell loss, from fractional viability, which more specifically reflects drug-induced killing. This framework improves interpretation of in vitro anticancer responses by preserving both response magnitude and timing, helping researchers separate cytostatic effects from cytotoxic effects.
-
Gastric Cancer Assembloids and Stromal Drug Response
2026-08-20
Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid model that combines matched tumor organoids with tumor-derived stromal subpopulations. The model reproduced broader tumor–microenvironment signaling than monocultures and revealed that stromal composition can alter drug sensitivity, providing a more informative platform for resistance studies and personalized treatment design.
-
10074-G5: A c-Myc Inhibitor for Cancer Research
2026-08-19
10074-G5 is a small-molecule c-Myc inhibitor that disrupts c-Myc/Max dimerization. Product data report micromolar activity in Daudi and HL-60 cells and tumor-growth suppression in a Daudi xenograft model, while mechanistic evidence connects c-MYC signaling with aggressive esophageal adenocarcinoma phenotypes.